Overview

Executive Assistant – Clinical Development and Medical Affairs (CDMA)

Reports to VP, Head of Medical Affairs, Solid Tumors

Opportunity

This is a great opportunity for an experienced administrator to join Menarini-Stemline and provide high-level administration and project support for both the VP Clinical Development, and the VP Medical Affairs (Solid Tumors). This role requires a highly effective collaborator who can work autonomously.

Responsibilities

• Partners with Finance and Procurement to manage purchase orders and invoices for Clinical Development and Medical Affairs related activities

• Partners with Legal and R&D to manage contracts, CDAs, NDAs and invoices for Clinical Development and Medical Affairs related activities

• Develops and manages various team collaboration sites and files.

• Oversees calendar and travel management (domestic and international).

• Works closely with Human Resources to coordinate and schedule onboarding introductory meetings, trainings, etc.

• Acts as a key contact both internally and externally.

• Manages group/company access to subscriptions & licenses to various information repositories, periodicals, databases, and software.

• Appropriately manages information of a highly confidential and critical nature.

• Arranges and provides support for internal/external meetings including team meetings, trainings, congresses.

• Takes the lead with coordinating group meetings and events, including agenda management, selection and management of venues and vendors to ensure seamless execution of events and presentations.

• Prepares materials for meetings, seminars, presentations, and special projects, often interfacing with key external stakeholders.

• Develops and manages various team collaboration sites and files.

• Provides additional support as needed to the team, depending on prioritization and bandwidth such as ordering supplies and materials, etc.

• Appropriately manages information of a highly confidential and critical nature.

• Performs other duties as assigned.

Qualifications

• 7-10 years of relevant Executive Assistant experience; and within Biotech/pharmaceutical industry preferred.

• Outstanding written and verbal communication skills.

• Attention to detail.

• Experience working with travel software such as Concur a plus.

• High-Level working knowledge of Microsoft Office Applications (PowerPoint, Excel, Word) and Google Workspace

• Experience working within a Global Organization.

• High integrity and demonstrated ability to treat confidential information with discretion.

• Strong organizational and prioritization skills.

• Proven collaborative team-player and pro-active self-starter.

• Ability to exercise good judgement, be forward thinking, and remain solution-oriented across a variety of situations.

• Ability to operate under tight deadlines in a multi-task role, with changing priorities in an exciting, rapidly growing company.

Please note: this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.

Base Salary Range of $115,500-$138,000. Menarini Stemline offers generous compensation and benefits packages, including Short -Term Incentive Programs, Fidelity 401(k) (with company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

#LI-PP1